Back to Authors

van der Steen, Travis

Mayo Clinic

Department of Urology Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Citations 2

The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells
Ji, Lu , Lonergan, Peter E. , Nacusi, Lucas P., Wang, Liguo , Schmidt, Lucy J., Sun, Zhifu , Steen, Travis Van der, Boorjian, Stephen A. , Kosari, Farhad , Vasmatzis, George , Klee, George G., Wang, Chunxi , Tindall, Donald J., Lu, Ji, van der Steen, Travis, Balk, Steven P. , Huang, Haojie , Sun, Zhifu , Wang, Liguo

Journal of Urology | August 14, 2014 | Volume: 193 | Issue: 2 | Pages: 690-698

10.1016/j.juro.2014.08.043 Get It

Posttranslational Modification of the Androgen Receptor in Prostate Cancer
Steen, Travis Van der, Tindall, Donald J., van der Steen, Travis, Huang, Haojie

International Journal of Molecular Sciences | July 17, 2013 | Volume: 14 | Issue: 7 | Pages: 14833-14859

10.3390/ijms140714833 Get It

The androgen receptor (AR) is important in the development of the prostate by regulating transcription, cellular proliferation, and apoptosis. AR undergoes posttranslational modifications that alter its transcription activity, translocation to the nucleus and stability. The posttranslational modifications that regulate these events are of utmost importance to understand the functional role of AR and its activity. The majority of these modifications occur in the activation function-1 (AF1) region of the AR, which contains the transcriptional activation unit 1 (TAU1) and 5 (TAU5). Identification of the modifications that occur to these regions may increase our understanding of AR activation in prostate cancer and the role of AR in the progression from androgen-dependent to castration-resistant prostate cancer (CRPC). Most of the posttranslational modifications identified to date have been determined using the full-length AR in androgen dependent cells. Further investigations into the role of posttranslational modifications in androgen-independent activation of full-length AR and constitutively active splicing variants are warranted, findings from which may provide new therapeutic options for CRPC.